Latvia has seen some major breakthroughs in recent years: more innovative medicines are available to patients than ever before; the market for commercial, OTC and reimbursable medicinal products has achieved new heights, and we are in a strong position to…
Dr Valters Bolevics, CEO of the Association of International Research-based Pharmaceutical Manufacturers (SIFFA) in Latvia, gives an overview of recent market changes affecting the Latvian pharmaceutical market, regulatory upgrades, and…
In terms of being able to access medicines, patients in the Baltic states fare poorly compared to many of their European counterparts. 135 new medicines were approved by regulators in…
Dr Valters Bolevics, director general of the Association of International Research-based Pharmaceuticals Manufacturers of Latvia (SIFFA), outlines the progress made on market access for innovative pharmaceuticals in Latvia in recent…
Latvia has seen some major breakthroughs in recent years: more innovative medicines are available to patients than ever before; the market for commercial, OTC and reimbursable medicinal products has achieved new heights, and we are in a strong position to continue this trend. What has been accomplished and what challenges is Latvia facing today with respect to innovation? Innovative…
Latvia has seen some major breakthroughs in recent years: more innovative medicines are available to patients than ever before; the market for commercial, OTC and reimbursable medicinal products has achieved…
Latvia has seen some major breakthroughs in recent years: more innovative medicines are available to patients than ever before; the market for commercial, OTC and reimbursable medicinal products has achieved…
Latvia has seen some major breakthroughs in recent years: more innovative medicines are available to patients than ever before; the market for commercial, OTC and reimbursable medicinal products has achieved…
See our Cookie Privacy Policy Here